The Compounding Loophole

The discussion dives into the economics of GLP-1 agonist drugs and the intriguing role of compounding pharmacies. It reveals how these pharmacies are leveraging legal loopholes to ensure access during shortages. A focus on compounded semaglutide showcases a potential cost-effective alternative but raises safety and regulatory concerns. The evolution of telemedicine post-COVID is also highlighted, with insights into the DEA's approach and the ethical dilemmas surrounding compounded medications.